Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

QSI

Quantum-Si Incorporated

Feb 13 • 12:36PM ET

1.03

+0.05 5.63 %

Healthcare • Medical Devices • USA • NASD

Peers: PACB BNGO BIO ILMN TWST CDNA NTRA TMO EXAS NTLA

| Held by: ARKG VTI IWM VXF IWN IBB VTWO VHT IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.66	Insider Own	20.03%	Shs Outstand	195.52M	Perf Week	-3.29%
Market Cap	221.95M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	-0.44%	Shs Float	172.33M	Perf Month	-18.90%
Enterprise Value	0.72M	PEG	-	EPS next Q	-0.12	Inst Own	27.57%	Short Float	10.94%	Perf Quarter	-32.24%
Income	-116.85M	P/S	69.80	EPS this Y	25.29%	Inst Trans	2.30%	Short Ratio	3.77	Perf Half Y	-8.04%
Sales	3.18M	P/B	0.94	EPS next Y	15.60%	ROA	-47.06%	Short Interest	18.86M	Perf YTD	-6.36%
Book/sh	1.09	P/C	0.98	EPS next 5Y	18.81%	ROE	-52.44%	52W High	3.10 -66.77%	Perf Year	-49.26%
Cash/sh	1.05	P/FCF	-	EPS past 3/5Y	16.08% 33.79%	ROIC	-49.11%	52W Low	0.92 11.38%	Perf 3Y	-50.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-82.91%	Volatility	9.28% 7.53%	Perf 5Y	-90.01%
Dividend TTM	-	EV/Sales	0.23	EPS Y/Y TTM	-4.07%	Oper. Margin	-3299.37%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.59	Sales Y/Y TTM	40.20%	Profit Margin	-3677.97%	RSI (14)	41.66	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	10.75	EPS Q/Q	3.94%	SMA20	-8.94%	Beta	3.01	Target Price	2.67
Payout	-	Debt/Eq	0.02	Sales Q/Q	-29.86%	SMA50	-15.40%	Rel Volume	0.71	Prev Close	0.98
Employees	149	LT Debt/Eq	0.01	Earnings	Nov 05 AMC	SMA200	-31.29%	Avg Volume	5.00M	Price	1.03
IPO	Nov 13, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.53% -7.89%	Trades		Volume	1,789,516	Change	5.63%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-07-25	Initiated	Alliance Global Partners	Buy	$3.75
Dec-08-23	Initiated	H.C. Wainwright	Buy	$3
Sep-25-23	Downgrade	Canaccord Genuity	Buy → Hold	$3.50 → $2
Oct-20-21	Initiated	Canaccord Genuity	Buy	$13

Feb-10-26 08:00AM	Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 (Business Wire)
Feb-05-26 08:00AM	Quantum-Si Announces the Release of Two New Manuscripts Demonstrating the Value of Single-Molecule Protein Sequencing in Clinical Proteomics and Pathogen & Toxin Detection (Business Wire) -9.50%
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga) +6.50%
Dec-22-25 08:00AM	Quantum-Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool Enhancements (Business Wire)
Dec-15-25 06:00PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
Nov-20-25 08:00AM	Quantum-Si Highlights Significant Development Advancements for Proteus and Industry Leading Technology Pipeline at Investor & Analyst Day (Business Wire)
Nov-19-25 08:00AM	Quantum-Si to Highlight Significant Proteus Platform Development Progress and Provide Insights into the Companys Industry Leading Technology Pipeline at Investor & Analyst Day (Business Wire)
Nov-06-25 12:05AM	Quantum-Si Inc (QSI) Q3 2025 Earnings Call Highlights: Innovation Milestones Amid Revenue Challenges (GuruFocus.com) -8.33%
Nov-05-25 07:50PM	Quantum-Si Incorporated (QSI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Quantum-Si Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 08:27AM	Earnings To Watch: Quantum-Si Inc (QSI) Reports Q3 2025 Result (GuruFocus.com) -8.00%
Oct-20-25 08:00AM	Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (Business Wire) +13.38%
Oct-14-25 08:25AM	Sono-Tek Corporation (SOTK) Q2 Earnings Beat Estimates (Zacks)
Oct-13-25 08:00AM	Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) +24.55%
Oct-10-25 04:35PM	Why Quantum-Si Stock Flopped on Friday (Motley Fool)
04:05PM	Loading…
Sep-15-25 04:05PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.78% +5.56%
Sep-08-25 08:00AM	Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing (Business Wire)
Aug-19-25 08:00AM	Quantum-Si to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) -5.50%
Aug-13-25 04:05PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 08:00AM	Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit (Business Wire)
Aug-07-25 11:58AM	Quantum-Si's Q2 Loss In Line With Estimates, Revenues Rise Y/Y (Zacks)
Aug-06-25 03:26AM	Quantum-Si Inc (QSI) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing New ... (GuruFocus.com)
Aug-05-25 06:45PM	Quantum-Si Incorporated (QSI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Quantum-Si Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 11:37AM	QSI Gears Up to Post Q2 Earnings: What's in Store for the Stock? (Zacks)
10:03AM	Earnings To Watch: Quantum-Si Inc (QSI) Reports Q2 2025 Result (GuruFocus.com)
Jul-21-25 08:00AM	Quantum-Si to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Jul-14-25 08:00AM	Quantum-Si to Report Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
Jul-04-25 10:45PM	Quantum-Si prices $50M registered direct offering of common stock at $1.67 (TipRanks)
Jul-03-25 08:34PM	Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock (Business Wire) +8.08% -14.72%
08:00AM	Loading…
Jun-24-25 08:00AM	Quantum-Si Platinum Pro Instrument Placed at the Broad Institute to Support Regional Research Initiatives (Business Wire) +13.94%
Jun-19-25 08:00AM	Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization (Business Wire)
Jun-17-25 08:00AM	Quantum-Si Customer to Showcase Protein Barcoding for Nucleic AcidLNP Therapeutic Development at Festival of Genomics Boston (Business Wire) -5.08%
Jun-13-25 04:05PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.26% +6.63%
Jun-10-25 08:00AM	Quantum-Sis Single-Molecule Tech Enables Precise, Multiplexed Measurement of Nanobody Binding in a Single Assay (Business Wire)
May-15-25 05:25PM	Quantum-Si Incorporated (QSI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Quantum-Si Reports First Quarter 2025 Financial Results (Business Wire)
May-13-25 05:45PM	QuickLogic (QUIK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-12-25 08:00AM	Dr. Gloria Sheynkman from the University of Virginia to Present Pioneering Research utilizing Quantum-Sis Next-Gen Protein Sequencing Platform in Upcoming Nature Webinar on May 15 (Business Wire) +19.84%
May-07-25 06:40PM	Silvaco Group, Inc. (SVCO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.83%
Apr-24-25 08:00AM	Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025 (Business Wire)
Mar-26-25 08:00AM	Quantum-Si Begins Shipping Platinum Pro, Advancing Accessibility in Next-Gen Protein Sequencing (Business Wire)
Mar-24-25 06:01AM	Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research (Business Wire)
Mar-20-25 08:00AM	Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research (Business Wire) -9.32%
Mar-17-25 11:09AM	Quantum computing, Affirm, Netflix upgrade: Market Minute (Yahoo Finance Video) +21.32%
Mar-13-25 04:05PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.00% +19.30%
Mar-03-25 04:05PM	Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire) -5.80% +6.15%
Feb-18-25 04:05PM	Quantum-Sis Customers and Researchers to Showcase Next-Generation Protein Sequencing at AGBT 2025 (Business Wire)
Feb-13-25 08:00AM	Quantum-Si and Researchers to Showcase Next-Generation Protein Sequencing at US HUPO 2025 (Business Wire)
Feb-12-25 08:00AM	Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (Business Wire)
Feb-11-25 08:00AM	Preprint from Northwestern University Highlights Complementary Proteomic Analysis of Interleukin-6 Using Next-Generation Protein Sequencing and Mass Spectrometry (Business Wire)
Feb-04-25 08:00AM	Quantum-Si Establishes Scientific Advisory Board to Shape Next-Generation Proteomic Technologies (Business Wire) +6.04%
Jan-28-25 08:00AM	Quantum-Si and IDEX Health & Science to Partner on Optics Module for Proteus Instrument (Business Wire) -5.88%
Jan-20-25 08:00AM	Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK (Business Wire)
Jan-18-25 08:05AM	Quantum-Si announces inducement grants under Nasdaq listing rule (TipRanks)
Jan-17-25 08:00AM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -11.81%
Jan-13-25 08:00AM	Quantum-Si Launches Platinum Pro: The End-to-End Solution for Deeper Insights in Proteomics (Business Wire) -27.03%
Jan-08-25 08:00AM	Quantum-Sis New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics (Business Wire) -24.46%
Jan-03-25 04:06PM	Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock (Business Wire)
Dec-20-24 08:00AM	Quantum-Si's New Preprint Showcases Advances in Protein Variant Detection using ProteoVue Software with Next-Generation Protein Sequencing (Business Wire)
Dec-18-24 08:00AM	Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.57%
Dec-12-24 05:00AM	Quantum-Si Expands International Distribution Network (Business Wire) -5.73%
Dec-04-24 08:30AM	Quantum-Si Launches Platinum New Library Prep Kit, Expanding Access to Next-Generation Protein Sequencing (Business Wire) +10.71%
Dec-03-24 08:30AM	Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening (Business Wire)
Nov-21-24 06:00AM	Quantum-Si Highlights Major Technical Advances, Next-Generation Platform Architecture and New Proteomic Applications at Investor and Analyst Event (Business Wire) -12.95%
Nov-20-24 07:30AM	Avantor to Distribute Quantum-Sis Next-Generation Protein Sequencing Technology (Business Wire) +119.59%
07:00AM	Quantum-Si to Develop Acceleration Platform and Advance Core Technologies in Collaboration with NVIDIA (Business Wire)
06:30AM	Quantum-Si Expands Collaboration with SkyWater to Develop New Chip Production Process Critical for Groundbreaking New Proteomics Platform (Business Wire)
06:00AM	Quantum-Si and Planet Innovation to Partner on Proteus (Business Wire)
Nov-18-24 04:01PM	Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.00%
Nov-13-24 06:00AM	Quantum-Si Honored with Frost & Sullivan's 2024 Technology Innovation Leadership Award for Next-Generation Protein Sequencing (Business Wire)
Nov-12-24 07:30AM	Quantum-Si Reports Third Quarter 2024 Financial Results (Business Wire) -22.43%
Nov-07-24 04:01PM	University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Sis Next-Gen Protein Sequencer Platinum (Business Wire)
Nov-05-24 09:00AM	Quantum-Si to Participate in Upcoming Investment Conferences (Business Wire) +11.92%
Oct-31-24 03:35PM	Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024 (Business Wire) -5.27%
Oct-30-24 06:00AM	Quantum-Si to Present at the 2024 American Society of Human Genetics Annual Meeting (Business Wire)
Oct-23-24 06:00AM	Quantum-Si to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (Business Wire)
Oct-17-24 05:21PM	Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-10-24 06:00AM	Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024 (Business Wire)
Sep-24-24 06:00AM	Northwestern Proteomics Center of Excellence Partners with Quantum-Si for Webinar on Advancing Proteoform Analysis with Top-Down Mass Spectrometry and Single-Molecule Sequencing (Business Wire)
Sep-19-24 06:00AM	Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024 (Business Wire) +6.00%
Sep-04-24 06:00AM	Liberate Bio Integrates Quantum-Si's Next-Generation Protein Sequencing Platform to Enhance Gene Therapy Development (Business Wire)
Aug-27-24 06:01PM	CORRECTING and REPLACING Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider (Business Wire)
04:30PM	Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider (Business Wire)
Aug-26-24 06:00AM	Quantum-Si to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -5.94%
Aug-07-24 04:02PM	Quantum-Si Reports Second Quarter 2024 Financial Results (Business Wire) -5.91%
Jul-30-24 04:05PM	Quantum-Si to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-17-24 04:05PM	Quantum-Si to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire) -6.03%
Jul-09-24 03:56PM	3 Super-Cheap Penny Stocks for the Ultimate Speculator (InvestorPlace)
Jun-10-24 09:00AM	Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata (Business Wire)
May-31-24 08:00AM	Quantum-Si Announces Presentations at ASMS and ESHG (Business Wire)
May-30-24 04:05PM	Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors (Business Wire)
May-09-24 04:01PM	Quantum-Si Reports First Quarter 2024 Financial Results (Business Wire) -7.10%
Apr-30-24 08:30AM	Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time (Business Wire)
Apr-18-24 04:05PM	Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Mar-21-24 04:05PM	Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors (Business Wire) -5.79%
Mar-07-24 12:01PM	Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing on Platinum at US HUPO Conference (Business Wire) +29.81%
Feb-29-24 04:05PM	Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +10.78%
Feb-27-24 08:30AM	Renowned Scientist Christopher Mason, Ph.D. and Quantum-Si Collaborate for Exclusive GenomeWeb Webinar (Business Wire) +5.36%

Quantum-Si, Inc. is a life sciences company focused on revolutionizing the growing field of proteomics. It engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins in a massively parallel fashion. Its platform includes platinum NGPS instrument, platinum analysis software, and consumable kits for platinum instrument. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vieceli John S.	Chief Product Officer	Dec 22 '25	Sale	1.28	21,927	27,979	800,973	Dec 22 08:11 PM
Vieceli John S.	Officer	Dec 22 '25	Proposed Sale	1.28	21,927	27,979		Dec 22 08:05 PM
LaPointe Christian	GC & Corp. Secretary	Dec 22 '25	Sale	1.28	11,951	15,249	948,855	Dec 22 08:01 PM
LaPointe Christian	Officer	Dec 22 '25	Proposed Sale	1.28	11,951	15,249		Dec 22 07:53 PM
Keyes Jeffry R.	Chief Financial Officer	Dec 22 '25	Sale	1.28	8,627	11,008	1,163,197	Dec 22 07:50 PM
Keyes Jeffry R.	Officer	Dec 22 '25	Proposed Sale	1.28	8,627	11,008		Dec 22 07:38 PM
Hawkins Jeffrey Alan	President & CEO	Dec 22 '25	Sale	1.28	23,707	30,250	2,578,018	Dec 22 07:29 PM
Hawkins Jeffrey Alan	Officer	Dec 22 '25	Proposed Sale	1.28	23,707	30,250		Dec 22 07:19 PM
Vieceli John S.	Officer	Sep 22 '25	Proposed Sale	1.66	19,686	32,655		Oct 20 08:10 PM
LaPointe Christian	Officer	Sep 22 '25	Proposed Sale	1.66	10,728	17,796		Oct 20 08:09 PM
Keyes Jeffry R.	Officer	Sep 22 '25	Proposed Sale	1.66	7,746	12,847		Oct 20 08:07 PM
Hawkins Jeffrey Alan	Officer	Sep 22 '25	Proposed Sale	1.66	21,286	35,308		Oct 20 08:06 PM
Bennett Todd C.	Officer	Sep 22 '25	Proposed Sale	1.66	36,964	61,316		Oct 20 07:46 PM
ROTHBERG JONATHAN M	Director	Oct 16 '25	Sale	3.07	26,095	80,112	1,904,866	Oct 17 07:05 PM
ROTHBERG JONATHAN M	Director	Oct 16 '25	Proposed Sale	3.07	26,095	80,166		Oct 16 07:42 PM
LaPointe Christian	GC & Corp. Secretary	Sep 22 '25	Sale	1.68	5,364	9,025	966,170	Sep 24 06:31 PM
LaPointe Christian	GC & Corp. Secretary	Sep 23 '25	Sale	1.64	5,364	8,770	960,806	Sep 24 06:31 PM
Hawkins Jeffrey Alan	President & CEO	Sep 22 '25	Sale	1.68	10,643	17,908	2,612,368	Sep 24 06:31 PM
Hawkins Jeffrey Alan	President & CEO	Sep 23 '25	Sale	1.64	10,643	17,401	2,601,725	Sep 24 06:31 PM
Vieceli John S.	Chief Product Officer	Sep 22 '25	Sale	1.68	9,843	16,562	832,743	Sep 24 06:31 PM
Vieceli John S.	Chief Product Officer	Sep 23 '25	Sale	1.64	9,843	16,093	822,900	Sep 24 06:31 PM
Keyes Jeffry R.	Chief Financial Officer	Sep 22 '25	Sale	1.68	3,873	6,517	1,175,697	Sep 24 06:31 PM
Keyes Jeffry R.	Chief Financial Officer	Sep 23 '25	Sale	1.64	3,873	6,332	1,171,824	Sep 24 06:31 PM
Bennett Todd C.	Chief Commercial Officer	Sep 22 '25	Sale	1.68	18,482	31,098	700,003	Sep 24 06:31 PM
Bennett Todd C.	Chief Commercial Officer	Sep 23 '25	Sale	1.64	18,482	30,218	681,521	Sep 24 06:31 PM
Hawkins Jeffrey Alan	President & CEO	Jun 23 '25	Sale	1.61	23,705	38,257	2,623,011	Jun 24 07:14 PM
Vieceli John S.	Chief Product Officer	Jun 23 '25	Sale	1.61	21,923	35,382	842,586	Jun 24 07:11 PM
LaPointe Christian	GC & Corp. Secretary	Jun 23 '25	Sale	1.61	11,946	19,280	971,534	Jun 24 07:06 PM
Keyes Jeffry R.	Chief Financial Officer	Jun 23 '25	Sale	1.61	8,624	13,918	1,179,570	Jun 24 07:03 PM
Hawkins Jeffrey Alan	President & CEO	Mar 21 '25	Sale	1.39	23,707	32,846	2,646,716	Mar 24 06:48 PM
LaPointe Christian	General Counsel & Corp. Secr.	Mar 21 '25	Sale	1.39	4,896	6,783	983,480	Mar 24 06:42 PM
Keyes Jeffry R.	Chief Financial Officer	Mar 21 '25	Sale	1.39	8,626	11,951	1,188,194	Mar 24 06:34 PM
Vieceli John S.	Chief Product Officer	Mar 21 '25	Sale	1.39	4,317	5,981	864,509	Mar 24 06:11 PM

Open in Screener

ORMP

Oramed Pharmaceuticals, Inc

Feb 13 • 12:36PM ET

3.31

+0.13 4.26 %

Healthcare • Biotechnology • USA • NASD

ORMP Oramed Pharmaceuticals, Inc daily Stock Chart

Peers: MNKD VTVT LGND TNDM XERS NVAX AQST CAPR RIGL

| Held by: IWC DFAC AVSC DFAS DCOR AVUS DFUS DXUV

Index	-	P/E	3.30	EPS (ttm)	1.00	Insider Own	22.65%	Shs Outstand	40.84M	Perf Week	-3.08%
Market Cap	131.54M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	30.79M	Perf Month	-2.60%
Enterprise Value	-3.24M	PEG	-	EPS next Q	-	Inst Own	23.61%	Short Float	2.09%	Perf Quarter	43.53%
Income	43.85M	P/S	65.77	EPS this Y	-	Inst Trans	-0.46%	Short Ratio	2.51	Perf Half Y	67.23%
Sales	2.00M	P/B	0.66	EPS next Y	-	ROA	22.75%	Short Interest	0.64M	Perf YTD	24.39%
Book/sh	4.98	P/C	0.98	EPS next 5Y	-	ROE	24.38%	52W High	3.71 -10.92%	Perf Year	44.70%
Cash/sh	3.38	P/FCF	-	EPS past 3/5Y	15.77% 10.71%	ROIC	21.51%	52W Low	1.70 94.79%	Perf 3Y	64.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-5.45%	Volatility	5.25% 5.62%	Perf 5Y	-67.77%
Dividend TTM	-	EV/Sales	-1.62	EPS Y/Y TTM	814.20%	Oper. Margin	-650.55%	ATR (14)	0.18	Perf 10Y	-42.26%
Dividend Ex-Date	Jan 16, 2026	Quick Ratio	22.24	Sales Y/Y TTM	196.74%	Profit Margin	2192.60%	RSI (14)	51.68	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.24	EPS Q/Q	335.86%	SMA20	-2.93%	Beta	1.32	Target Price	3.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.76%	Rel Volume	0.30	Prev Close	3.17
Employees	13	LT Debt/Eq	0.00	Earnings	Aug 13	SMA200	40.24%	Avg Volume	257.29K	Price	3.31
IPO	Mar 19, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1800.00% -	Trades		Volume	38,889	Change	4.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold	$30 → $3
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight	$20
Apr-20-21	Initiated	Canaccord Genuity	Buy	$27
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy	$11
Mar-11-20	Initiated	Aegis Capital	Buy	$5.50
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$7
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy	$20
May-26-16	Reiterated	FBR Capital	Outperform	$15 → $20
Dec-01-15	Reiterated	H.C. Wainwright	Buy	$24 → $25
Nov-19-15	Initiated	FBR Capital	Outperform	$15
Apr-13-15	Resumed	MLV & Co	Buy	$27 → $30
Jan-30-14	Reiterated	Aegis Capital	Buy	$30 → $35
Jan-08-14	Reiterated	Aegis Capital	Buy	$25 → $30
Jan-08-14	Initiated	MLV & Co	Buy	$27
Dec-03-13	Initiated	Aegis Capital	Buy	$25

Show Previous Ratings

Jan-13-26 07:58AM	Oramed and Lifeward Announce Strategic Transaction (PR Newswire)
Jan-07-26 08:55AM	Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments (PR Newswire) +6.51%
Nov-17-25 08:56AM	Oramed Reports Fiscal Third Quarter 2025 Financial Results (PR Newswire)
08:50AM	ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS (PR Newswire)
Nov-13-25 05:51PM	Oramed: Q3 Earnings Snapshot (Associated Press Finance)
08:55AM	Loading…
Oct-23-25 08:55AM	Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives (PR Newswire)
Aug-14-25 06:40PM	Oramed: Q2 Earnings Snapshot (Associated Press Finance)
May-15-25 06:16PM	Oramed: Q1 Earnings Snapshot (Associated Press Finance)
May-09-25 06:18PM	WEX, Acelyrin, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-28-25 09:00AM	Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical (PR Newswire)
09:00AM	Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals (GlobeNewswire)
Mar-04-25 09:00AM	Oramed Pharmaceuticals Issues Letter to Shareholders (PR Newswire) +7.00%
Feb-11-25 09:15AM	Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin (PR Newswire) +19.82%
Dec-16-24 09:00AM	Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Oct-07-24 10:00AM	Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt (PR Newswire)
05:12AM	Loading…
Aug-15-24 05:12AM	Oramed: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-24 03:07PM	3 Micro-Cap Moonshots for Fearless Investors (InvestorPlace)
Jun-26-24 09:05AM	Oramed Letter to Shareholders (PR Newswire) +14.73%
09:00AM	Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock (PR Newswire)
May-09-24 11:53PM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
06:51PM	Oramed: Q1 Earnings Snapshot (Associated Press Finance)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-07-24 10:53AM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Oramed Letter to Shareholders (PR Newswire)
Nov-10-23 05:03AM	Oramed: Q3 Earnings Snapshot (Associated Press Finance)
Oct-24-23 08:30AM	PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization (PR Newswire)
Oct-05-23 10:13AM	ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801 (Zacks)
Sep-22-23 11:38AM	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company (PR Newswire)
Sep-21-23 06:11PM	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company (PR Newswire)
04:05PM	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. (GlobeNewswire)
09:00AM	Loading…
Sep-13-23 09:00AM	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder (GlobeNewswire) -5.56%
Aug-02-23 07:45AM	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally (PR Newswire)
Jun-20-23 07:55AM	Oramed to Present at the 83rd American Diabetes Association Conference (PR Newswire)
Jun-17-23 09:54AM	Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-30-23 11:06AM	ORMP: Advancing Development Efforts in China (Zacks Small Cap Research)
May-18-23 07:55AM	Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit (PR Newswire) +13.22%
May-15-23 09:05AM	Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China (PR Newswire) +10.60%
May-12-23 01:03PM	Oramed: Q1 Earnings Snapshot (AP Finance)
May-02-23 10:51AM	Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company (Bloomberg) +6.53%
May-01-23 04:45PM	Oramed Appoints Ben Shapiro to its Board of Directors (PR Newswire) +7.93%
Mar-27-23 06:57AM	The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable (Simply Wall St.)
Feb-09-23 07:55AM	Oramed Pharmaceuticals Issues Shareholder Update (PR Newswire) +5.77%
Jan-25-23 08:05AM	ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts (Zacks Small Cap Research)
Jan-12-23 12:30PM	Oramed Pharmaceuticals Stock Plummets After Insulin Test Results (The Wall Street Journal) -76.46%
11:50AM	Why Oramed Pharmaceuticals Stock Is Crashing Today (Motley Fool)
08:02AM	Orameds oral insulin pill fails; stock is down 72% (MarketWatch)
06:19AM	Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study (Benzinga)
Jan-11-23 08:00PM	Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes (PR Newswire) +5.78%
Jan-08-23 07:38AM	Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation (Simply Wall St.)
Jan-04-23 07:55AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire)
Dec-21-22 08:25AM	Oramed Letter to Shareholders (PR Newswire) +14.25%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 08:40AM	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism (PR Newswire)
Nov-21-22 10:45AM	ORMP: Data from NASH Phase 2 Study Positive Takeaways (Zacks Small Cap Research)
Nov-17-22 01:12PM	Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study (Benzinga)
12:25PM	Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire)
Nov-16-22 05:06AM	Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -8.56%
Nov-14-22 07:55AM	Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea (PR Newswire)
Nov-10-22 04:30PM	Oramed Reports Third Quarter 2022 Financial Results (PR Newswire) +5.96% +14.74%
Nov-09-22 08:40AM	Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire) -6.19%
Oct-17-22 08:07AM	Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years (Simply Wall St.) +7.69%
Oct-07-22 11:06AM	Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study (Benzinga) -7.19%
08:40AM	Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine (PR Newswire)
Sep-13-22 11:59AM	Oramed Oral Insulin Shows Evidence For NASH Treatment (Benzinga)
08:40AM	Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate (PR Newswire)
Sep-06-22 07:55AM	Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) -12.36%
Aug-25-22 09:15AM	ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts (Zacks Small Cap Research)
Aug-01-22 07:40AM	We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-26-22 07:55AM	Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial (PR Newswire)
Jul-12-22 02:22PM	Why Oramed Pharmaceuticals Stock Is On Fire Today (Motley Fool)
Jul-11-22 07:55AM	Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference (PR Newswire) +5.61%
Jul-08-22 05:56PM	Why Oramed Pharmaceuticals Stock Rocketed Higher Today (Motley Fool) +44.37%
Jul-07-22 07:55AM	Oramed Letter to Shareholders (PR Newswire) +12.70%
Jun-01-22 07:55AM	Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board (PR Newswire) -5.40%
May-24-22 08:10AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire) -5.23%
May-18-22 07:55AM	Oramed to Present at H.C. Wainwright Global Investment Conference (PR Newswire) -13.42%
May-10-22 07:12AM	Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week (Simply Wall St.) -6.12%
May-03-22 08:10AM	Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1 (PR Newswire)
Apr-27-22 08:10AM	ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing (Zacks Small Cap Research)
Apr-05-22 08:25AM	Oramed Granted NASH Patent in Europe (PR Newswire)
Apr-04-22 08:25AM	Oramed Appoints Yadin Rozov to its Board of Directors (PR Newswire)
Mar-29-22 08:25AM	Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians (PR Newswire)
Mar-22-22 08:25AM	Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes (PR Newswire)
Mar-16-22 08:25AM	Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial (PR Newswire) +6.88%
Mar-10-22 08:25AM	Oramed to Present at Barclays Global Healthcare Conference (PR Newswire)
Feb-23-22 11:25AM	ORMP: Moving Multiple Candidates & Studies Forward (Zacks Small Cap Research) -6.11%
Feb-22-22 05:38AM	We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate (Simply Wall St.)
Jan-12-22 08:45AM	Oramed Issues Annual Message to Shareholders (PR Newswire)
Jan-05-22 07:30AM	Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins (PR Newswire) -8.29%
Dec-29-21 06:14AM	Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh (MarketWatch)
06:00AM	Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia (PR Newswire)
06:00AM	Israel's Oramed gets Vietnam pre-order for 10 mln COVID-19 vaccine doses (Reuters)
Dec-14-21 08:00AM	Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa (PR Newswire) -6.76%
Dec-08-21 07:30AM	Oramed Pharmaceuticals Appoints Chief Legal Officer (PR Newswire)
Nov-24-21 08:40AM	Oramed to Join MSCI USA Small Cap Index (PR Newswire)
Nov-23-21 08:25AM	Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study (PR Newswire)
Nov-18-21 07:40AM	Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (PR Newswire)
Nov-11-21 09:25AM	Oramed to Present at H.C. Wainwright 7th Annual Israel Conference (PR Newswire)
Nov-10-21 10:19AM	ORMP: Financing Enhances Flexibility to Advance Multiple Opportunities (Zacks Small Cap Research) -6.30%
Nov-08-21 08:10AM	Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) +10.88%

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Hexter Joshua	COO & CBO	Jan 22 '26	Option Exercise	19,000	1,064,495	Jan 29 04:05 PM
Kidron Miriam	Chief Scientific Officer	Jan 22 '26	Option Exercise	19,000	1,448,664	Jan 29 04:05 PM
Gabay Avraham	Chief Financial Officer	Jan 22 '26	Option Exercise	19,000	649,256	Jan 29 04:05 PM
KIDRON NADAV	President and CEO	Jan 22 '26	Option Exercise	109,000	3,355,238	Jan 29 04:05 PM

QSI

Quantum-Si Incorporated

ORMP

Oramed Pharmaceuticals, Inc

Upgrade your FINVIZ experience